|Bid||85.69 x 5200|
|Ask||85.76 x 1000|
|Day's Range||85.08 - 86.90|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||32.46|
|Dividend & Yield||2.72 (3.29%)|
|1y Target Est||85.75|
A European Medicines Agency panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. ...
Healthcare leads markets after the release of the Senate health plan.
Novartis stock rocketed to a five-month high Thursday after the drugmaker's anti-inflammatory proved successful in a trial.